2006
Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients
Liu PP, Maggioni A, Velazquez EJ. Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients. Journal Of The Renin-Angiotensin-Aldosterone System 2006, 7: s19-s22. PMID: 16986231, DOI: 10.3317/jraas.2006.019.Peer-Reviewed Original ResearchConceptsAng II receptor blockersHeart failureLV dysfunctionMyocardial infarctionStrong therapeutic rationaleUse of valsartanII receptor blockersLeft ventricular dysfunctionHeart failure patientsPost-MI patientsMain effector mechanismPost-myocardial infarctionLarge-scale trialsRAAS blockadeAldosterone systemReceptor blockersVentricular dysfunctionAssociated morbidityFailure patientsFrequent complicationSuch patientsACE inhibitorsSignificant morbiditySuch therapyDisease progression
2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial
Jamerson K, Bakris G, Wun C, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez E, Weber M. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. American Journal Of Hypertension 2004, 17: 793-801. PMID: 15363822, DOI: 10.1016/j.amjhyper.2004.05.004.Peer-Reviewed Original ResearchConceptsSystolic Hypertension (ACCOMPLISH) trialCardiovascular eventsBlood pressureHypertension trialsCombination therapyOptimal BP controlPrimary study endpointCalcium channel blockersClass of drugsBP controlCardiovascular outcomesHypertensive patientsPrimary endpointCardiovascular mortalityStudy endpointACE inhibitorsHypertension managementFirst patientClinical eventsAntihypertensive combinationsRisk factorsSuch therapyRecent guidelinesDrug classesVasculoprotective properties